oral plasma kallikrein serine protease inhibitor

approved for prevention of HAE attacks

from structure-based drug design

Journal of Medicinal Chemistry

BioCryst, Birmingham, AL, USA

berotralstsat

The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353), was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg QD) despite having…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: